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Renal Protective Effects and
the Prevention of Contrast-Induced
Nephropathy by Atrial Natriuretic Peptide
Shuji Morikawa, MD,* Takahito Sone, MD,* Hideyuki Tsuboi, MD,* Hiroaki Mukawa, MD,*
Itsuro Morishima, MD,* Michitaka Uesugi, MD,* Yasuhiro Morita, MD,*† Yasushi Numaguchi, MD,‡
Kenji Okumura, MD,§ Toyoaki Murohara, MD†
Ogaki and Nagoya, Japan
Objectives This study was designed to examine the protective effects of atrial natriuretic peptide (ANP) on contrast-induced
nephropathy (CIN) after coronary angiography.
Background Contrast-induced nephropathy is a common complication after angiography. Some studies have shown that ANP
has renal protective effects, but the beneficial effects for CIN prevention remain to be clearly shown.
Methods In a prospective, controlled, randomized trial in 254 consecutive patients with serum creatinine concentrations of
1.3 mg/dl, patients received either ANP (0.042 g/kg/min; ANP group, n  126) or Ringer solution alone (control
group, n  128). Treatment of either type was initiated 4 to 6 h before angiography and continued for 48 h.
Results There were no significant differences in age, sex, diabetes mellitus, or baseline serum creatinine level between
the 2 groups. The prevalence of CIN, defined as a 25% increase in creatinine or an increase in creatinine of
0.5 mg/dl from baseline within 48 h, was significantly lower in the ANP group than in the control group (3.2%
vs. 11.7%, respectively; p  0.015). Multivariate analysis revealed that the use of 155 ml of contrast medium
(odds ratio: 6.89; p  0.001) and ANP treatment (odds ratio: 0.24; p  0.016) were significant predictors of
developing CIN. The incidence of an increase in creatinine of 25% or of 0.5 mg/dl from baseline at 1 month
was also significantly lower in the ANP group than in the control group (p  0.006).
Conclusions In addition to hydration, ANP administration is effective in the prevention of CIN in patients with chronic renal
failure, and the effect was maintained for 1 month. (J Am Coll Cardiol 2009;53:1040–6) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.061t
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rontrast-induced nephropathy (CIN) is one of the most
mportant clinical complications associated with coronary
ngiography, accounting for 10% of all causes of hospital-
cquired renal failure (1,2); it has been reported to occur in
1% to 44% of patients with moderate renal insufficiency
1,3). Contrast-induced nephropathy is associated with
onsiderably increased morbidity and mortality, including
he need for transient dialysis and/or extended hospitaliza-
ion, and can lead to chronic end-stage renal disease (1,3,4).
lthough several prevention strategies have been investi-
ated extensively in recent years, no optimal strategy for
reventing CIN has yet been established. The most recent
uidelines (5) recommend intravenous volume expansion,
rom the *Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan;
Department of Cardiology, Nagoya University Graduate School of Medicine,
agoya, Japan; and ‡Medical Science of Proteases and §Cardiovascular Research
edicine, Nagoya University School of Medicine, Nagoya, Japan.i
Manuscript received June 4, 2008; revised manuscript received September 19, 2008,
ccepted October 13, 2008.he use of low- or iso-osmolality contrast media, and limits
n the volume of contrast media.
See page 1047
Atrial natriuretic peptide (ANP) is a potent endoge-
ous diuretic and natriuretic substance (6) that has been
hown to improve renal function and perfusion in animal
odels (7,8) and in clinical ischemic renal failure (9 –11).
nimal studies have shown ANP to be beneficial in
reventing CIN, but clinical studies (12–14) have not yet
rovided clear results; 1 clinical study failed to show any
eneficial effect of the short-term administration of ANP
ith respect to CIN (14). The present study was a
rospective, randomized, single-center control trial to
valuate the effect of the middle-term administration of
NP on the occurrence of CIN in patients with chronic
enal insufficiency undergoing coronary angiography or
ntervention.
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atients. This single-center (Ogaki Municipal Hospital),
andomized controlled trial compared infusion of ANP in
ddition to intravenous hydration with hydration alone in
reatment to prevent renal failure in patients with chronic
enal insufficiency undergoing coronary angiography or
ntervention. Consecutive eligible patients between the ages
f 20 and 85 years who had a serum creatinine concentration
f 1.3 mg/dl and 6 mg/dl were considered for enroll-
ent. The indications for the procedure were determined by
ach patient’s cardiologist. Exclusion criteria were preg-
ancy, lactation, acute renal failure, end-stage renal failure
n dialysis, acute myocardial infarction, multiple myeloma,
ulmonary edema, cardiogenic shock, a systolic blood pres-
ure of 110 mm Hg, dehydration, a history of allergies to
ontrast media or ANP, having received contrast media
ithin 7 days of the study entry, having received an infusion
f ANP within 1 month of the study entry, parenteral use of
iuretics, and the administration of dopamine, N-acetylcysteine,
etformin, sodium bicarbonate, fenoldopam, mannitol, or
onsteroidal anti-inflammatory drugs (NSAIDs) during the
tudy. The study protocol was approved by the local ethics
ommittee, and all patients provided their written, informed
onsent before study entry.
tudy protocol. Patients were randomly assigned to receive
ither 0.042 g/kg/min of ANP (Carperitide, Asubio
harma Co., Ltd., Tokyo, Japan, and Daiichi-Sankyo Co.,
td., Tokyo, Japan) plus 1.3 ml/kg/h of Ringer solution,
oth intravenously (ANP group), or Ringer solution alone
control group) before and after contrast administration.
he ANP and Ringer solution infusions were initiated 4 to
h before the angiographic procedure and continued for
8 h after it. All patients were encouraged to drink if they
ere thirsty. Iomeprol (Iomeron 400, Eisai Co., Ltd.,
okyo, Japan), a nonionic, low-osmolality contrast medium,
as used in all patients. All decisions regarding procedural
emodynamics, including contrast volume, were left to the
iscretion of the cardiologist. We calculated the sample size
f our study assuming a CIN rate of 15% in the control
roup based on the rate previously reported in patients
ndergoing coronary angiography (15). Moreover, we as-
umed that the incidence of CIN decreases to almost
ne-fourth by the administration of ANP. Using a 2-sided
hi-square test with a significance level of 0.05 and 80%
ower, 122 patients would be necessary in each group.
Serum creatinine and cystatin C were measured at 12 to
4 h before the procedure and at 24 h, 48 h, 1 week, and 1
onth after the procedure. The glomerular filtration rate
GFR) was calculated using the level-modified Modification
f Diet in Renal Disease modified for Japanese: estimated
lomerular filtration rate (eGFR)  0.741  175  age in
ears0.203  serum creatinine1.154; with female sex ad-
ustment: eGFR female  eGFR  0.742 (16). Urinary2-microglobulin and N-acetyl--D-glucosaminidase pNAG) were measured at 12 to
4 h before the procedure, and at
8 h, 1 week, and 1 month after
he procedure.
The primary end point was the
ncidence of CIN, defined as a
5% increase in creatinine or an
ncrease in creatinine of 0.5
g/dl from baseline at the max-
mum value obtained within 48 h
fter the procedure (17,18). The
ollowing secondary end points
ere also assessed: 1) a 25% in-
rease in creatinine within 48 h;
) an increase in creatinine of
0.5 mg/dl from baseline within
8 h; 3) changes in serum creat-
nine, eGFR and serum cystatin C concentrations, and
rinary 2-microglobulin and NAG until 1 month after the
rocedure; and 4) a 25% increase in creatinine or an increase
n creatinine of 0.5 mg/dl from baseline at 1 month after
he procedure.
tatistical analysis. Statistical analysis was based on an
ntention-to-treat analysis for all subjects after initial ther-
py. Categorical variables were expressed as percentages and
nalyzed by the chi square or Fisher exact test, as appropri-
te. Continuous variables were expressed as mean SD and
ompared with the Student t test unless otherwise indicated.
hen data were not normally distributed, they were ex-
ressed as median and interquartile ranges and compared
ith the nonparametric Mann-Whitney U test. Two-way
epeated-measures analysis of variance was used to test for
inear trend in eGFR. Univariate and multivariate analysis
etermined which factors correlated with developing CIN.
he volume of contrast media to predict CIN was used to
etermine the optimal cutoff value (155 ml; sensitivity,
8.4%; specificity, 75.7%) by receiver-operator characteristic
urve analyses. Values of p  0.05 were considered to be
tatistically significant. All statistical analyses were per-
ormed using the Statistical Package for the Social Sciences
ersion 13.0 (SPSS Inc., Chicago, Illinois).
esults
atient demographics. A total of 272 patients were ini-
ially enrolled in the study. However, 4 patients refused to
articipate in the study and 7 patients were excluded (5
atients, systolic blood pressure of 110 mm Hg; 2 pa-
ients, chronic dialysis). Of the 261 patients who were
andomized, 254 completed the study. Seven patients did
ot complete the study; 4 patients did not obtain follow-up
erum creatinine concentration levels. One patient of these
did not have a creatinine concentration taken 24 h after
he procedure, and the remaining 3 did not have a creatinine
oncentration taken 48 h after the procedure. In all 4
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
CI  confidence interval
CIN  contrast-induced
nephropathy
eGFR  estimated
glomerular filtration rate
LVEF  left ventricular
ejection fraction
NAG  N-acetyl--D-
glucosaminidase
NSAID  nonsteroidal anti-
inflammatory drugsatients, serum creatinine concentration was assessed 1
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ailure, and the serum creatinine concentration available at
ollow-up did not reach an increase of 25% or an increase
f 0.5 mg/dl from baseline. Three patients committed
rotocol violations; all received NSAIDs. Thus, 126 ANP
atients and 128 control patients were included in the
rotocol analysis (Fig. 1).
aseline characteristics. The baseline characteristics of
he patients are shown in Table 1. The number of patients
ith hypertension, diabetes mellitus, and a history of
ongestive heart failure or myocardial infarction was similar
etween the ANP and control groups, as was the number
eceiving angiotensin-converting enzyme inhibitors, angio-
ensin II receptor blocker, calcium-channel blockers, diuret-
cs, and statins before the angiographic procedure. There
ere no significant differences in left ventricular ejection
raction (LVEF) measured before the procedure. The
VEF was measured primarily by radionuclide or contrast
entriculography; if these were not available, echocardiog-
aphy was used. The mean contrast volume administered
id not differ significantly between groups.
In terms of renal function, there were no significant
ifferences between the 2 groups in baseline serum creati-
ine, eGFR, cystatin C, urinary 2-microglobulin, or NAG
efore the procedure (Table 2).
Figure 1 Randomization and Clinical Diagnoses in All Patients
ANP  atrial natriuretic peptide; NSAID  nonsteroidal anti-inflammatory drug.[hanges in renal function and prevalence of CIN. When
ompared with the control group, ANP infusion of 0.042
g/kg/min produced a significant decrease in systolic blood
ressure (9.3  14.7 mm Hg vs. 3.2  14.6 mm Hg at
4 h and 8.0  20.0 mm Hg vs. 2.7  14.0 mm Hg at
8 h; both p  0.001), with an increase in the 2-day urine
olume (4,067  1,068 ml vs. 3,686  1,254 ml; p 
.042). The changes in serum creatinine, eGFR and serum
ystatin C, and urinary parameters of 2-microglobulin and
AG at 24 h, 48 h, 1 week, and 1 month after the
rocedure are shown in Table 2. In the control group, there
as a more significant deterioration than in the ANP group
f serum creatinine, eGFR, and cystatin C from 48 h to 1
onth after the procedure. However, there were no statis-
ically significant differences between the 2 groups in
hanges in urinary 2-microglobulin or NAG at 48 h, 1
eek, and 1 month from baseline values.
The eGFR gradually and slightly deteriorated until 1
eek, and was mildly improved at 1 month in the control
roup, whereas a similar deterioration was observed at 24 h
n the ANP group, but was completely restored at 1 week
nd remained at baseline levels until 1 month (p 0.016 for
he interaction of group with linear trend) (Fig. 2).
Figure 3 shows the incidence of CIN using different
riteria. The incidence of an increase in serum creatinine of
25% or of 0.5 mg/dl from baseline was significantly
ower in the ANP group (n  4 of 126, 3.2%) than in the
ontrol group (n 15 of 128, 11.7%) (p 0.015; odds ratio
aseline Characteristics of Study Patients
Table 1 Baseline Characteristics of Study Patients
ANP Group
(n  126)
Control Group
(n  128) p Value
Age, yrs 74 9 73 8 0.68
Male 90 (71.4) 92 (71.9) 0.93
Height, cm 158 7 159 7 0.87
Weight, kg 60.5 10 59.8 9 0.53
Blood pressure (systolic), mm Hg 129 11 131 11 0.10
Hypertension 93 (73.8) 100 (78.1) 0.42
Diabetes mellitus 51 (40.5) 63 (49.2) 0.16
History of congestive heart
failure
49 (38.9) 42 (32.8) 0.31
History of myocardial infarction 57 (45.2) 55 (43) 0.71
Medication
ACE inhibitors 20 (15.9) 14 (10.9) 0.25
Angiotensin II receptor
inhibitors
62 (49.2) 74 (57.8) 0.17
Calcium-channel blockers 78 (61.9) 80 (62.5) 0.92
Diuretics 63 (50.0) 72 (56.3) 0.31
Statins 79 (62.7) 82 (64.1) 0.82
LVEF, % 52 14 53 13 0.28
40 25 (19.8) 23 (18.1) 0.72
Volume of contrast media, ml 139 62 140 72 0.92
155 32 (26.8) 37 (28.9) 0.68
alues are expressed as n (%) or mean  SD.
ACE  angiotensin-converting enzyme; ANP  atrial natriuretic peptide; LVEF  left ventricular
jection fraction.OR]: 0.25; 95% confidence interval [CI]: 0.08 to 0.77).
T
m
(
C
c
c
0
f
i
c
a
o
z
i
u
T
6
0
p
d
c
v
1
8
H

g
0

(
0

i
(
v
0
a
1
g

O
d
f
ucosam
1043JACC Vol. 53, No. 12, 2009 Morikawa et al.
March 24, 2009:1040–6 Effect of ANP on Contrast-Induced Nephropathyhe incidence of an increase in serum creatinine of 0.5
g/dl was 8.6% (n  11) in the control group and 2.4%
3 patients) in the ANP group (p  0.042; OR: 0.26; 95%
I: 0.07 to 0.95). The incidence of an increase in serum
reatinine of25% from baseline was 10.9% (n 14) in the
ontrol group and 3.2% (n  4) in the ANP group (p 
.023; OR: 0.27; 95% CI: 0.09 to 0.84).
By univariate analysis, there were 2 significant predictive
actors for the incidence of CIN, which was defined as an
ncrease of 0.5 mg/dl or 25% from baseline serum
reatinine level, contrast volume of 155 ml, and ANP
dministration (Table 3). The LVEF, anemia, and the use
f other medications such as angiotensin-converting en-
yme inhibitors or statins were not associated with the
ncidence of CIN. Only variables with a value of p  0.2 on
nivariate analysis were included in the multivariate model.
he use of contrast volume of 155 ml (p  0.001; OR:
.89; 95% CI: 2.4 to 19.3) and ANP administration (p 
.016; OR: 0.24; 95% CI: 0.07 to 0.77) were independent
redictors for developing CIN. The eGFR levels in patients
iagnosed with CIN were much improved at 1 month when
ompared with those at 48 h (25.7  6.7 ml/min/1.73 m2
Changes From Baseline in Serum Creatinine,eGFR, Cystatin C, Uri ary 2-Microglobul , and
Table 2 Changes From Baseline in Serum CeGFR, Cystatin C, Urinary 2-Microg
ANP Group (n 
Serum creatinine (mg/dl)
Baseline 1.57 (1.341
Change at 24 h 0.02 (0.08
Change at 48 h 0.025 (0.12
Change at 1 week 0.02 (0.26
Change at 1 month 0.025 (0.10
eGFR (ml/min/1.73 m2)*
Baseline 29.4 9.
Change at 24 h 0.61 3.
Change at 48 h 0.31 4.
Change at 1 week 0.47 4.
Change at 1 month 0.15 5.
Serum cystatin C (mg/l)
Baseline 1.89 (1.622
Change at 24 h 0.02 (0.15
Change at 48 h 0.03 (0.20
Change at 1 week 0.01 (0.22
Change at 1 month 0.02 (0.15
Urinary 2-microglobulin (g/l)
Baseline 288 (52.81
Change at 24 h 313 (322,2
Change at 1 week 52 (230
Change at 1 month 2 (617
Urinary NAG (U/l)
Baseline 7.7 (4.914
Change at 24 h 0.5 (4.2
Change at 1 week 0.9 (3.0
Change at 1 month 0.5 (3.6
Values are median and interquartile ranges, and statistics were obta
statistics were obtained by the Student t test.
eGFR  estimated glomerular filtration rate; NAG  N-acetyl--D-gls. 21.2  7.9 ml/min/1.73 m2 in the control group [n  c5; p  0.001] and 33.7  6.7 ml/min/1.73 m2 vs. 27.2 
.4 ml/min/1.73 m2 in the ANP group [n 4; p 0.057]).
owever, the incidence of an increase in serum creatinine of
0.5 mg/dl at 1 month was 9.4% (n  12) in the control
roup and 1.6% (n 2) in the ANP group (p 0.016; OR:
.16; 95% CI: 0.03 to 0.71). The incidence of an increase of
25% was 11.7% (n  15) in the control group and 1.6%
n  2) in the ANP group (p  0.006; OR: 0.12; 95% CI:
.03 to 0.54). The incidence of an increase of 25% or of
0.5 mg/dl from baseline at 1 month was 12.5% (n  16)
n the control group and 2.4% (n  3) in the ANP group
p  0.006; OR: 0.17; 95% CI: 0.05 to 0.60). On multi-
ariate analysis, the use of contrast volume of 155 ml (p
.001) and no use of ANP (p  0.006) were significantly
ssociated with worse renal function at 1 month. There were
9 patients in the control group and 5 patients in the ANP
roup with an increase in serum creatinine of0.5 mg/dl or
25% from baseline during 1-month follow-up (p 0.006;
R: 0.24; 95% CI: 0.09 to 0.66).
One patient in the control group required temporary
ialysis, but there was no significant difference in the need
or dialysis between therapies (p  0.32). The event of
ine,
lin, and NAG
Control Group (n 128) p Value
1.55 (1.361.90) 0.99
0.04 (0.070.14) 0.36
0.055 (0.090.17) 0.029
0.07 (0.170.20) 0.001
0.06 (0.040.25) 0.004
29.3 8.2 0.87
0.84 4.25 0.64
0.86 5.25 0.047
1.29 4.85 0.004
1.24 6.00 0.048
2.05 (1.692.37) 0.41
0.03 (0.120.23) 0.36
0.03 (0.140.20) 0.042
0.09 (0.080.21) 0.001
0.04 (0.120.27) 0.015
452 (86.82,340) 0.29
452 (3.52,910) 0.64
) 28 (315722) 0.46
2 (445524) 0.67
6.5 (3.913.2) 0.072
0.3 (2.83.9) 0.36
1.5 (1.94.1) 0.45
0.4 (1.85.5) 0.68
y Mann-Whitney U test. *Values are expressed as mean  SD, and
inidase; other abbreviations as in Table 1.NAG
reatin
lobu
126)
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ut no other major adverse events were observed.
iscussion
e showed in the present study that intravenous ANP
dministration in addition to hydration during 48 h reduces
he incidence of CIN and renal dysfunction in patients with
hronic renal insufficiency undergoing coronary angiogra-
hy or intervention.
The pathophysiology of CIN is poorly understood, and
ittle is known about the underlying cellular mechanisms
17); however, they certainly involve the interplay of mul-
iple factors. After contrast exposure, there is a brief period
f vasodilatation followed by renal vasoconstriction, which
s presumably triggered by angiotensin, vasopressin, and
ndothelin, resulting in a decrease in renal blood flow (18).
oreover, the stasis of iodinated contrast in the renal
ubules and collecting ducts allows for direct cellular injury
o and death of renal tubular cells (18,19). The ANP has
een reported to have beneficial effects on the events
nduced by contrast media. These include natriuretic effects;
or example, increasing the GFR by dilating the afferent
rterioles while constricting the efferent arterioles (20). The
NP also blocks the tubular reabsorption of sodium and
hloride, redistributes renal medullary blood flow, and
isrupts tubuloglomerular feedback (21,22). With respect to
irculating humoral factors, ANP antagonizes the secretion
f renin and aldosterone (23) and suppresses endothelin
elease (24). These renal effects of ANP may prevent CIN
y decreasing the period of renal hypoperfusion, ischemia,
nd the stasis of contrast media. Renal dysfunctions are
Figure 2 Changes in eGFR After Angiography
Changes in estimated glomerular filtration rate (eGFR) between baseline and
24 h, 48 h, 1 week, and 1 month after angiography. Data are mean  SD, and
were analyzed by 2-way repeated-measures analysis of variance. Control group
is shown by the triangle and dotted line; atrial natriuretic peptide (ANP) group
is shown by the circle and solid line.lassified as glomerular, indicated by creatinine, eGFR, andystatin C levels, and tubular, potentially measured by
rinary NAG activity and 2-microglobulin. The renal
rotective effects of ANP were found to be expressed in
reatinine, eGFR, and cystatin C levels, but not in 2-
icroglobulin or NAG levels. The present findings indicate
hat ANP is likely to protect glomerular and hemodynamic
unctions rather than renal tubular function.
The biggest problem in the present study was determin-
ng how long ANP should be administered and what dose of
NP should be used. Previous studies have examined the
ffects of ANP on renal outcome in acute renal failure of
arious etiologies. One study showed that ANP infusion
0.01, 0.05, or 0.1 g/kg/min) initiated 30 min before and
ontinued for 30 min after the angiographic procedure did
ot reduce the incidence of CIN in patients with chronic
enal insufficiency (14). In another study, ANP had no
eneficial effect on the need for dialysis in a heterogeneous
roup of patients with acute renal failure (25). The failure to
how a clear-cut beneficial effect of ANP in acute renal
ailure in these studies could be explained by an excessive
ose of ANP (0.2 g/kg/min) and a short infusion period.
ecause these studies showed that patients treated with
NP had significantly lower blood pressure than control
roups, ANP infusion might induce a marked and sudden
ecrease in blood pressure, followed by reduced renal
erfusion, particularly in cases of acute renal failure, which
s characterized by a loss of autoregulatory capacity (26).
dditionally, hypotension may account for the lack of
eneficial effect by ANP administration. In contrast, an-
ther study showed that ANP infused at a rate of 0.05
g/kg/min for 5 days decreased the probability of dialysis in
schemic acute renal failure after cardiac surgery (27).
urthermore, it has previously been shown in patients with
Figure 3 Incidence of CIN in the ANP
Group Compared With the Control Group
ANP  atrial natriuretic peptide; CIN  contrast-induced nephropathy.
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March 24, 2009:1040–6 Effect of ANP on Contrast-Induced Nephropathyschemic acute renal failure that ANP at an infusion rate of
.05 g/kg/min induces selective dilatation of the renal
fferent arterioles with an increase of approximately 40%
n renal blood flow and GFR without any major hemo-
ynamic disturbances, such as a decrease in systemic
ascular resistance or mean arterial pressure; these effects
re not achieved with a low dose of ANP (0.025 g/kg/
in) (11). In these studies, however, most patients
eceived dopamine for arterial pressure support during
he study period. Without dopamine, ANP might have
nduced a marked and sudden decrease in blood pressure.
he results of these previous studies led us to choose an
nfusion rate of 0.042 g/kg/min and infusion for 48 h
fter the procedure in addition to a 4- to 6-h infusion
efore it; our selected dose and infusion time could
xplain the beneficial effects of ANP on renal outcome in
he present study.
CIN is diagnosed when serum creatinine concentrations
each a peak value within 1 to 2 days after contrast media
dministration with an increase over the baseline concen-
ration lasting 1 to 5 days (18,28). However, the serum
reatinine peak is postponed in patients with pre-existing
mpaired renal function, and the increase may last for 7 to
1 days (29). In the present study, we measured cystatin C
s well as serum creatinine and eGFR until 1 month after
he procedure. Cystatin C has been identified as a novel
iomarker that is more sensitive in detecting early kidney
ysfunction than creatinine and eGFR (30). Because it is
onceivable that cystatin C, a marker of GFR, is not affected
y tubular transport, it has been recommended to include
erum level monitoring of cystatin C when assessing kidney
unction in patients undergoing coronary angiography (31).
n the present study, serum creatinine, eGFR, and cystatin
levels were deteriorated, reaching a trough at 1 week after
he procedure, and the deterioration persisted even up to 1
Univariate Analysis for CIN
Table 3 Univariate Analysis for CIN

Age 70 yrs 73.7%
Hypertension 78.9%
Diabetes mellitus 57.9%
History of myocardial infarction 47.4%
Anemia 57.9%
ACE inhibitors or ARBs 68.4%
Calcium-channel blockers (alone) 15.8%
Diuretics 52.6%
Statins 57.9%
LVEF 40% 15.8%
Contrast media 155 ml 68.4%
Baseline creatinine 2.0 mg/dl 21.1%
ANP administration 21.1%
Anemia was defined as a hematocrit level of 39% for men or of 3
ACE  angiotensin-converting enzyme; ANP  atrial natriuretic
nephropathy; LVEF  left ventricular ejection fraction.onth in the control group. In contrast, although there was Msimilar deterioration of these markers for kidney dysfunc-
ion at 24 h in the ANP group, they then improved
onsiderably and renal functions were restored to baseline by
month after the procedure. These findings indicate that
NP administration has beneficial effects on renal functions
or at least 1 month. It has been shown that even small
hanges in the deterioration of renal function can have a
ignificant impact on mortality (3,32). This was recently
onfirmed in a large database of 27,608 patients who were
reated with contrast media during coronary angiography
33). Thus, the prevention of small changes in renal func-
ion may be important, as seen in the present study with
espect to serum creatinine, eGFR, and cystatin C levels.
Larger contrast volumes have been associated with an
ncreased risk of CIN (18). The nephritic effect of contrast
edia is dose dependent: ordinarily, the higher the dose, the
igher the risk for CIN (17). Although no definitive threshold
imit of contrast volume has yet been established, contrast
olumes100 to 200 ml are associated with a higher incidence
f CIN in high-risk patients (17,28). In the present study,
ultivariate analysis showed that the incidence of the deteri-
ration of renal function even at 1 month after the procedure
ere independently prevented by ANP administration regard-
ess of using a contrast volume 155 ml.
tudy limitations. The present study was a single-center
tudy and was not blinded. A larger, multicenter, double-
linded, adequately powered randomized trial is required to
onfirm the beneficial effects of ANP administration on CIN.
onclusions
he present study shows that a systemic protocol of con-
inuous intravenous hydration with ANP is a safe and
ffective method of preventing CIN in patients with chronic
enal insufficiency undergoing angiographic procedures.
 Odds Ratio p Value
74.9% 0.95 0.91
75.7% 1.20 1.00
43.8% 1.76 0.24
43.8% 0.87 0.77
67.2% 0.67 0.45
66.4% 1.10 0.86
9.8% 1.73 0.42
53.2% 0.98 0.96
63.8% 1.28 0.61
19.6% 0.77 1.00
24.3% 6.77 0.001
20.9% 1.01 1.00
51.9% 0.25 0.015
women.
; ARB  angiotensin II receptor blocker; CIN  contrast-inducedCIN
6% fororeover, renal function is maintained by ANP up to 1
m
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ibility that ANP administration may reduce long-term
ortality as well as the initiation of dialysis after coronary
ngiography and intervention.
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